lufepirsen
Phase 2/3- Indications
- Persistent corneal epithelial defects (PCED)
Company intelligence / Profile preview
Amber Ophthalmics
San Diego, California, United Statesamberophthalmics.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Phase 2
01
Overview
Amber Ophthalmics’ lead candidate Nexagon (lufepirsen ophthalmic gel) has shown promising results in a Phase 2 trial for PCED, with 67% of treated patients achieving complete corneal epithelial recovery versus 27% on placebo. The ongoing NEXPEDE‑1 study is a randomized, double-masked, vehicle-controlled Phase 2/3 trial evaluating two concentrations of Nexagon for PCED. The company’s approach leverages an unmodified antisense oligonucleotide targeting connexin43 to restore ocular homeostasis and promote healing in rare anterior segment eye diseases.
- Therapeutic areas
- Ophthalmology
- Modalities
- Antisense oligonucleotides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Amber Ophthalmics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amber Ophthalmics.